Marksans Pharma jumps 11% post USFDA nod for anti-allergy drug

Shares of Marksans Pharma settled with a nearly 11 per cent gain today after it received approval from USFDA for loratadine liquid-filled capsules, used for treatment of allergies, in the American market.
The stock climbed 10.76 per cent to end the day at Rs 53 on BSE. Intra-day, it jumped 12.53 per cent to Rs 53.85.
At NSE, shares of the company climbed 10.58 per cent to settle at Rs 52.75.
On the volume front, 59.10 lakh shares changed hands on BSE and over 2 crore at NSE.
"USFDA has granted approval for an abbreviated new drug application (ANDA) for loratadine liquid-filled capsules 10 mg," Marksans Pharma said in a BSE filing.

Loratadine liquid-filled capsules are therapeutically equivalent to the reference listed drug Claritin Liqui-Gels Capsules 10 mg of Bayer Healthcare LLC, it said.
Loratadine is an anti-histamine that reduces the effect of natural chemical histamine in the body. It is used for treating sneezing, runny nose, watery eyes, hives, skin rash, itching and other allergy symptoms.